Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs
- PMID: 2062811
- DOI: 10.1023/a:1015870521744
Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs
Abstract
A chemically modified, amorphous beta-cyclodextrin, namely, 2-hydroxypropyl-beta-cyclodextrin (HPCD), was examined as a solubilizing and stabilizing agent for protein drugs. The aqueous solubility of ovine growth hormone at pH 7.4 was increased through the use of HPCD. This effect was manifested by higher UV transparency at 600 nm. Interleukin-2 (IL-2) is rendered insoluble upon lyophilization in the absence of stabilizers. Use of aqueous HPCD provides a clear solution, as indicated by fluorometric light scattering, and inhibits aggregate formation, as shown by ultracentrifugation and Western blot analyses. In addition, there were no major conformational changes of IL-2 in HPCD formulation as indicated by fourth-derivative ultraviolet spectroscopy. Finally, IL-2 retained 100% of its biopotency when prepared in HPCD solutions. Aggregation of insulin was also suppressed by HPCD. These data, as well as the i.v. safety of HPCD and its well-characterized chemical composition, suggest that this starch derivative may be a potentially useful excipient for protein drugs intended for parenteral use.
Similar articles
-
Influence of hydroxypropyl-beta-cyclodextrin on the transdermal permeation and skin accumulation of oxybenzone.Drug Dev Ind Pharm. 2002 Oct;28(9):1117-24. doi: 10.1081/ddc-120014578. Drug Dev Ind Pharm. 2002. PMID: 12455470
-
Solubilization of ovine growth hormone with 2-hydroxypropyl-beta-cyclodextrin.J Parenter Sci Technol. 1991 Nov-Dec;45(6):266-9. J Parenter Sci Technol. 1991. PMID: 1802981
-
Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate.Pharm Res. 1991 Dec;8(12):1495-9. doi: 10.1023/a:1015838215268. Pharm Res. 1991. PMID: 1808612
-
HP-β-CD for the formulation of IgG and Ig-based biotherapeutics.Int J Pharm. 2021 May 15;601:120531. doi: 10.1016/j.ijpharm.2021.120531. Epub 2021 Mar 26. Int J Pharm. 2021. PMID: 33775727 Review.
-
The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems.Pharmazie. 2002 Feb;57(2):94-101. Pharmazie. 2002. PMID: 11878196 Review.
Cited by
-
Inhibition of insulin fibrillogenesis with targeted peptides.Protein Sci. 2006 May;15(5):1133-41. doi: 10.1110/ps.051879606. Epub 2006 Apr 5. Protein Sci. 2006. PMID: 16597825 Free PMC article.
-
Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins.Pharm Res. 2005 Oct;22(10):1735-46. doi: 10.1007/s11095-005-6489-4. Epub 2005 Sep 22. Pharm Res. 2005. PMID: 16180132
-
Structural basis for cyclodextrins' suppression of human growth hormone aggregation.Protein Sci. 2002 Jul;11(7):1779-87. doi: 10.1110/ps.0202702. Protein Sci. 2002. PMID: 12070330 Free PMC article.
-
Integrating Stimuli-Responsive Properties in Host-Guest Supramolecular Drug Delivery Systems.Theranostics. 2019 May 15;9(11):3017-3040. doi: 10.7150/thno.31913. eCollection 2019. Theranostics. 2019. PMID: 31244940 Free PMC article. Review.
-
Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices.Pharm Res. 1995 Jun;12(6):838-43. doi: 10.1023/a:1016252802413. Pharm Res. 1995. PMID: 7667187
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources